Podcasts about Melendi

El Real Oviedo tiene nuevo himno del centenario, compuesto por Melendi. Lo comentamos y aprovechamos para descubrir curiosidades en torno a los himnos oficiales de Real Sporting y Real Oviedo. También hablamos del aumento de los tratamientos de medicina estética. Según un reciente estudio, casi la mitad de la población accede a este tipo de tratamientos. Nos acompañaron Pablo Behache, Teresa Denisse, María Álvarez, Josep Henarejos y Miguel Ángel Muñiz.

Desayunamos entre dinosaurios para contaros que crece la familia del MUJA. La instalación ha incorporado a su colección la réplica de un diplodocus. Además felicitamos al asturiano Melendi, que se ha convertido en el artista que más entradas de conciertos vende en España, y al luarqués que ha ganado un millón de euros en La Primitiva. Por último nos fuimos a Gijón para degustar las mejores hamburguesas de la ciudad. Desayunamos con Santi Robles, Lorena Rendueles y Nathalie García. Por cierto, como cada martes, escuchamos un nuevo episodio del podcast “Redescubriendo a Tino Casal”, presentado por Ramón Palicio.

Dial tal cual (Tramo de 10:00 a 11:00)

Roi, antes conocido como Roi Méndez, presenta su nuevo single Perfecto desastre en Cuerpos especiales. El cantante habla de su alter ego R01 y entra en el juego de Eva Soriano y Nacho García. Se atreve a imitar a Melendi, Eros Ramazzotti y Raphael cantando canciones de otros. 

La cantante María Isabel se ha pasado por Cuerpos especiales para presentar Ansiedad, su nuevo single en el que aborda la necesidad de poner en valor la salud mental y desvelar todos los detalles sobre cómo se tatuó en un concierto de Melendi mientras sonaba Antes muerta que sencilla. Además, Laura del Val da las pautas legales para saber qué hacer con los conductores de autobús que cierran la puerta a los pasajeros, Nacho García analiza la actualidad del Corazón, con especial mensaje a Marta Díaz, y Bertus se sumerge con el Proyecto Abigail del Área 51, pero acaba en la carretera de Valencia.

La cantante María Isabel se ha pasado por Cuerpos especiales para presentar Ansiedad, su nuevo single en el que aborda la necesidad de poner en valor la salud mental, además de desvelar todos los detalles sobre cómo se tatuó en un concierto de Melendi mientras sonaba Antes muerta que sencilla y dar todos los detalles sobre su nueva gira por 20 aniversario del lanzamiento de su álbum No me toques las palmas que me conozco.

Dial tal cual (Tramo de 10:00 a 11:00)

La remontada de Osasuna en Copa del Rey en Ceuta por Melendi

08 07-11-24 LHDW Dos críticas antagónicas de la última peli de Clint Eastwood. Canción más triste y alegre de la historia según los científicos. Canción de Melendi

08 07-11-24 LHDW Dos críticas antagónicas de la última peli de Clint Eastwood. Canción más triste y alegre de la historia según los científicos. Canción de Melendi

02 06-11-24 LHDW Noticias del NoDo: Reacciones de la Sexta a la victoria de Trump, parecía un funeral. Melendi y su canción para Valencia. Más de políticos

02 06-11-24 LHDW Noticias del NoDo: Reacciones de la Sexta a la victoria de Trump, parecía un funeral. Melendi y su canción para Valencia. Más de políticos

Vicco ofrece un Secret Show en Barcelona muy especial. Boza protagoniza LOS40 Global Show de esta semana. Melendi muestra su apoyo a los afectados por la DANA en Valencia. Muere Quincy Jones a los 91 años. Maluma anuncia su gira '+Pretty +Dirty World Tour 2025'.

GALVAN REAL, NICOLE, BECKY HILL, LEWIS THOMPSON, ISABEL AAIUN, SHAZOOZEY, JC REYES, MARIA ARTES, MAKI, MELENDI y más Feliz fin de semana para todos/as Disfruten y pasenlo genial Nos escuchamos si Dios quiere y volvemos a encontrar el próximo lunes Paz y música

Entre los clientes de este pequeño taller de guitarras artesanales en Alicante se encuentran Sabina, Estopa, Melendi y los Rolling Stones

Dial tal cual (Tramo de 12:00 a 13:00)

Robe, Eats Everything, Stevie Appleton, Pedro Javier Hermosilla, Siloé, Melendi, El Bicho, Rulo y Contrabanda -23/09/24 Gracias a todos por las muestras de cariño antes ésta conjuntivitis vírica que nos tiene fastidiados y que nos está afectando tanto. Esperamos recuperar lo más pronto que podamos. Gracias de corazón a todos por estar ahi y perdón por no poder ofreceros un programa mejor en el dia de hoy. Paz y música.

Temazos sin pausa, gracias a todos los que venis a disfrutar con Estación GNG dia tras dia; hoy os pusimos un montón de canciones nuevas y algunos clasicazos pasados... entre otras hoy os recomendamos estos temas que hoy sonaron en Estación GNG : Depol - Dime solo si has pensao Lola Indigo - Pesadillas Juan Magán, Uri, Briella, Mar Lucas -- Hiki ( Remix ) Peggy Gou - It Goes Like Galván Real - Amor Eterno El Columpio Asesino - Toro Ana Mena, Emilia - Carita Triste El Alfa, Darell, Noriel - 4K Chandé, Raúl El Balilla - AMIGO Melendi, Manuel Carrasco - Con la Luna LLena Gracias a todos los que seguis colaborando con nuestro programa a diario, enviando mensajes a nuestra linea whatsapp y hablándonos en redes sociales, recordad que nos podeis encontrar por ahi en redes como #musicaguillermonieto o como @estaciongng .... y en whatsapp os leemos a todos/as en el 693938377. Paz y música y feliz fin de semana.

On March 26, 1994, 19-year-old Shannon Melendi disappeared during her lunch break while working as a softball scorekeeper, never to be seen again. Initially treated as a runaway, it wasn't until political pressure mounted that authorities took the case seriously, but by then, crucial evidence had vanished. Sign the petition here to keep Shannon's murderer behind bars! Also mentioned in the episode, Safely self-defense products.  Thank you to this week's sponsors! Stop wasting money on things you don't use. Cancel your unwanted subscriptions by going to RocketMoney.com/MOMS.  Honeylove is not just supporting women, it's empowering women. Treat yourself to the best bras on the market and save 20% Off at honeylove.com/MOMS20..  Start getting your best sleep this fall with Boll & Branch. Enjoy 15% off plus free shipping on your first set of sheets at  BollAndBranch.com with promo code MOMS.  To advertise on the show, contact sales@advertisecast.com or visit https://www.advertisecast.com/MomsandMysteriesATrueCrimePodcast.  New merch! Check out Moms and Mysteries Threadless! You can also get new episodes a day early and ad free, plus merch and more at Patreon.com/momsandmysteriespodcast Listen and subscribe to Melissa's other podcast, Criminality!! It's the podcast for those who love reality TV, true crime, and want to hear all the juicy stories where the two genres intersect. Subscribe and listen here: www.pod.link/criminality  Check-out Moms and Mysteries to find links to our tiktok, youtube, twitter, instagram and more! Make sure you subscribe and rate our show to help others find us! Sources: http://www.dcor.state.ga.us/GDC/Offender/Query https://www.change.org/p/victimservices-pap-state-ga-us-keep-shannon-melendi-s-murderer-colvin-butch-hinton-behind-bars-where-he-belongs?recruiter=877139825&recruited_by_id=43c89870-5ddf-11e8-aa67-0978a971054a&utm_source=share_petition&utm_medium=copylink&utm_campaign=petition_dashboard https://www.newspapers.com/image/403699963/?terms=shannon%20melendi&match=1 https://www.newspapers.com/image/403700225/?terms=shannon%20melendi&match=1, https://www.newspapers.com/image/403700256/  https://www.newspapers.com/image/403209738/?terms=claudette%20ficik&match=1 https://www.newspapers.com/image/403871519/?terms=claudette%20ficik&match=1 https://www.newspapers.com/image/403700864/?terms=shannon%20melendi&match=1 https://casetext.com/case/hinton-v-state-63?q=colvin%20hinton&p=1&tab=keyword&jxs=&sort=relevance&type=case https://www.sun-sentinel.com/opinion/fl-xpm-2014-03-25-sfl-timeline-of-death-20140325-story.html https://abcnews.go.com/TheLaw/LegalCenter/story?id=2201120&page=1 Due to character limitations, additional sources are available upon request. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Magazine de ocio, actualidad y cultura de Vigo.En Hoy por Hoy Vigo hemos hablado con la conselleira de Vivenda ePlanificación de Infraestruturas, María Martínez Allegue. Tambiénconocimos más detalles sobre los planes de recuperación de lafortaleza y la muralla de Vigo de la mano del alcalde, Abel Caballero.El presidente de Conxemar, Eloy García, nos explicó más detalles delConxefest que organiza la feria internacional para conmemorar su 25aniversario. El histórico Carlos Miguel nos ha contado que pasa a serpresidente del Polideportivo Saudade sustituyendo a su mentor ymaestro, Paco Amoedo. El presidente del Celta Femxa Zorka nos contó elinicio de la pretemporada de su equipo. También conocimos la historiade Mari Carmen. Una mosense en silla de ruedas que no pudo ver elconcierto de Melendi en Castrelos y que va a cumplir su sueño enPonferrada. El artista le ha invitado al concierto de este sábado.Dani Lorenzo nos trajo las novedades del cine y del Festival de

Todos los jueves Fernando Urban nos trae la historia de un disco de bandas y artistas de Argentina y el mundo.

Anexos al abecé de la música popular de Brasil en forma de compilaciones. Intervienen: Alejandro Sanz, Lucrecia, Antonio Vega, Presuntos Implicados, Jorge Drexler, Melendi, Ana Belén, Martínez Ares, Café Quijano, Pastora Soler, Javier Álvarez, Soraya Ravenle, Sabrina Korgut, Juliana Diniz, Pedro Paulo Malta, Alfredo del Penho y Eduardo Dusek.Escuchar audio

Maurici i Esteve Alfaras, directors del Menorca Music Festival, han visitat el Bacstage de Flaixbac per explicar-nos totes les novetats del festival que se celebrarà del 2 al 9 d'agost al recinte firal d'Es Mercadal i que comptarà amb artistes de la talla de Nil Moliner, Stay Homas, Guillem Gisbert, Melendi o David Bisbal. #MenorcaMusicFestival #Menorca

Melendi, Ana Mena, Camela, Sopa de Cabra o el xelista Hauser són a punt d'exhaurir entrades per als seus concerts al Festival Terramar Caixabank d'enguany. La de Sitges, en alguns casos, serà l'única actuació dins la província de Barcelona, un fet que no és menor i que té valor en tant que la competència de festivals a Barcelona i rodalies és àmplia. Més enllà dels artistes la recerca de patrocinis és l'altra pota clau en l'organització d'un Festival com el de Jardins de Terramar, apostar per un municipi petit i no per una gran ciutat no sempre és l'elecció de grans marques alhora d'invertir diners, en aquest sentit el codirector del Festival Terramar Caixabank desitjaria més treball en la promoció de Sitges en la resta del territori nacional. L'entrada Després del sold out de Ludovico Einaudi el Festival Jardins de Terramar és a punt d’exhaurir entrades en quatres concerts més ha aparegut primer a Radio Maricel.

Puedes seguirme en https://www.alternatribu.com/ y https://vivedistinto.com/ Hoy vengo a contarte mi experiencia de un evento que estoy seguro que te interesa: El Gran Reserva Emprendedores que se ha celebrado del 20 al 22 de junio en Calahorra (La Rioja). El concepto ha sido guapísimo, mezclar un festival de música con emprendedores; por la mañana teníamos charlas con emprendedores y empresarios de alto nivel y por la tarde podíamos acceder a los conciertos que se celebraban, con músicos y grupos como La oreja de Van Gogh, Melendi, Luis Fonsi, Bustamante... No es que sean mis grupos favoritos, pero estuvo genial poder ver a artistas de tanto renombre. Lo que sí que me apasionó fue el evento de emprendedores, ubicado en el teatro Ideal y orquestado por Rafel Mayol, el organizador, cada día teníamos charlas desde las diez de la mañana y hasta las tres de la tarde con invitados de lujo. Me hizo especial ilusión ver la charla de José Elías, pero la que me impresionó fue la de Anxo Pérez, un showman en toda regla. No te voy a comentar más del evento, lo que quiero contarte es que en este tipo de eventos se conoce a gente interesante. Merece mucho la pena. En dos días he conocido a personas que me han propuesto negocios en Costa Rica, estancias y experiencias para emprendedores en las Maldivas y he conseguido contactos para entrevistas para el podcast Emprendedores de Éxito. Además, he sacado contenido e ideas nuevas para mis propios proyectos. En eventos de emprendedores te das cuenta que: No estás solo, hay mucha más gente de la que piensas en tu misma situación. Hay personas haciendo cosas increíbles por el mundo. Estas personas tienen tantas ganas como tú de conocer a otros emprendedores. Se pueden sacar miles de ideas de escuchar a los demás. Por otro lado, me llevo otro aprendizaje del evento: me alegro de haber cancelado el festival de Nómadas y Emprendedores Digitales que estaba organizando en La Ràpita. Porque por mucho que merezca la pena ir a este tipo de eventos, hay detrás un esfuerzo y trabajo descomunal que muchas veces pasa desapercibido y no se valora como debe -chapó por el equipo de la organización-. Si quieres emprender, ves sin duda a este tipo de eventos, dejarás de sentirte solo, aprenderás y conocerás a personas interesantes. Puedes seguirme en https://www.alternatribu.com/ y https://vivedistinto.com/

Taylor Swift pone fin a su gira The Eras Tour. Aitana confiesa tener listas dos colaboraciones internacionales en relación con sus futuros proyectos. David Bisbal y Juanjo Bona (OT) compartirán escenario en el Wizink Center de Madrid. Melendi se emociona al cantar el himno del Real Oviedo. Dani Fernández anuncia su nueva canción Criminal.

El cantante asturiano, en 'Carrusel Canalla', tras cantar en la previa del Real Oviedo - RCD Espanyol.

Inglaterra ha cerrado el tercer día de la Eurocopa con una ajustada victoria ante Serbia. Los miembros de 'El Sanedrín' lo analizan, así como el día posterior al triunfo de España en su debut ante Croacia. Además, charlamos con Melendi, que ha cantado en la previa del triunfo del Real Oviedo al RCD Espanyol en la ida de la final del 'play-off' de ascenso a Primera.

El cantante asturiano, en 'Carrusel Canalla', tras cantar en la previa del Real Oviedo - RCD Espanyol.

Inglaterra ha cerrado el tercer día de la Eurocopa con una ajustada victoria ante Serbia. Los miembros de 'El Sanedrín' lo analizan, así como el día posterior al triunfo de España en su debut ante Croacia. Además, charlamos con Melendi, que ha cantado en la previa del triunfo del Real Oviedo al RCD Espanyol en la ida de la final del 'play-off' de ascenso a Primera.

El profesor y poeta Nacho Tajahuerce explora el vínculo entre la enseñanza y la poesía. Un recurso que emplean los maestros que quieren formar a sus alumnos con pensamiento crítico. Suenan Platero y tú, Melendi o Jetro Tull.

Poema de Antonio Choperena como introducción a un tema interpretado por Melendi

Dial tal cual (Tramo de 11:00 a 12:00)

El artista asturiano ha pasado este lunes por los micrófonos de Radioestadio Noche. 

Dial tal cual (Tramo de 12:00 a 13:00)

Dial tal cual (Tramo de 12:00 a 13:00)

JENNIFER LOPEZ, MALU, LUIS FONSI, PONCHO K, AITANA, KIKO Y SHARA, EL BARRIO, JOASE, WATERMAT, MELENDI, OBK y muchos más . Comenta nuestros programas de ésta semana y consigue un nº para el SORTEO de la SMART TV de 50 pulgadas que ponemos en liza y que sortearemos el dia de REYES con el SORTEO DEL NIÑO... Ultimas 3 cifras del gordo del niño será el que dictamine el ganador de dicha tele.... Date prisa que en 3 dias han participado casi 400 personas, no te quedes sin tu número... comenta y luego pasaremos a contestarte con el número que tienes para el sorteo. IMPTT : La tele se envia en Península Ibérica, no fuera de ella. PAZ Y MUSICA

Acabem la setmana amb humor i m

Nos Tienen Contentas, un podcast que se publica cada dos semanas los miércoles. Hoy tenemos como invitado a Arkano campeón nacional de Red Bull Batalla de Gallos con solo 15 años, batió el record guiness tras estar improvisando más de 24 horas y 34 minutos en la Puerta del Sol de Madrid, quizás lo habéis visto en Masterchef Celebrity, Pasapalabra o La Voz Kids y además ha colaborado con Alejandro Sanz y Melendi, es una persona muy natural y que da gusto escuchar. Déjanos en comentarios qué sección te ha gustado más, el tema, el consultorio o la ruleta de las preguntas Mándanos tu duda al WhatsApp de 722436960 para el Consultorio Contento ️ Síguenos en redes: https://www.instagram.com/nostienencontentas/ https://www.tiktok.com/@nostienencontentas https://www.instagram.com/roenlared/ https://www.instagram.com/paulaalvarezsexologa/

Dial tal cual (Tramo de 11:00 a 12:00)

Three victims; Shannon Melendi, Nick Markowitz and Margie Jelovcic and three mothers (and fathers) who broke my heart over their sadness of all three of their very strange and unusual deaths, discussed here, on the Right Shoe.

08 19-10-23 LHDW Música: Vuelve Melendi un poco despistado, Madonna y su gira. Rammstein y su espectáculo en directo, llega a España. Madonna ya tiene 65 años

Queda sin resolver qué suda Rüdiger. De camino a tener más Eurocopas que Vicente Miera. Indudable sorpasso de Joselu a Haaland. Lecciones del fútbol de la calle. Qué tienen los Bryan. Negarse a Netflix pero no a Beckham. Más zorro que Simeone. Qué sería de Magic sin Melendi. Academia de destecnificación y motes. El gusto por sorprenderse con documentales. Años y cejas chungas. Todos pasamos por un barbecho. El meme infinito e infalible. Duro golpe de Marc Cardona en Villarreal. La maldición de las natillas. Más le vale ser zurdo a Arda Güler. Revisionismo no del todo justo con algunos goles. Expresiones atinadas en el Ajax. La mentira del jogo bonito.

JCO PO author Alexander E. Drilon, MD, shares insights into his article, “Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers” and the article's findings of the activity of larotrectinib in patients with advanced lung cancer harboring NTRK gene fusions. Host Dr. Rafeh Naqash and Dr. Drilon discuss drug development, testing for fusions, resistance mechanisms, and cancer metastases. Click here to read the article!   TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I am your host, Dr. Rafeh Naqash, Social Media Editor for JCO Precision Oncology, and Assistant Professor at the OU Stephenson Cancer Center.  Today we are excited to be joined by Dr. Alexander Drilon, Chief of the Early Drug Development Service and Medical Oncologist on the Thoracic Oncology Service at the Memorial Sloan Kettering Cancer Center and lead author of the JCO Precision Oncology article “Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers.” Our guests' disclosures will be linked in the transcript.  Dr. Drilon, welcome to the podcast and thank you for joining us today. We're really excited to be discussing this topic with you.  Dr. Alexander Drilon: It's my pleasure and thank you for the invitation. Dr. Rafeh Naqash: For the sake of this podcast, we will refer to each other using our first names. So, Alex, you've led the development for some of these agents targeting NTRK. So it's really timely that you're coming onto this podcast to not just discuss this very interesting paper that you published in JCO Precision Oncology, but also the general landscape of NTRK. So could you briefly tell us about the history of the drug development process behind NTRK fusions, when it started, how you got involved, and where it stands currently? Dr. Alexander Drilon: Sure. So, as you mentioned, my background is in lung cancer, where when I came on as a fellow, there was a lot of excitement around EGFR and ALK, but then subsequently other oncogene drivers were also discovered and many of them were fusion. So, as we know, ALK in the fuse state is a driver of many tumors, as is ROS1 and RET. And interestingly, NTRK fusions share many similarities with ALK, RET, and ROS1 in that you have an intact kinase domain that's in the three prime position, it's fused to a different gene in the five prime position and basically describes oncogenesis.  And the beautiful thing about NTRK fusions is that they are widely found across many different cancers. And I like to think of these cancers in two major buckets. So there is a bucket for cancers that are rare where we see these NTRK fusions with a very high frequency. And examples here are your secretory carcinomas of the salivary gland and the breast, for example, more congenital fibrosarcoma, where the frequency exceeds 90% in some series, and then there are much more common tumors where the frequency is much lower. So lung cancer is an example where you find it in less than 1% of cases. There are some other tumors like GI cancers also where the frequency is low. And beyond these two major groups, we also see these NTRK fusion-positive cancers occur not just in the adult population, but the pediatric population. All of that thrown together means that it was a really great setup for exploring the activity and safety of targeted therapy in what we call a ‘basket trial' paradigm, where you design a trial and instead of selecting patients based on cancer type, you ignore cancer type and, of course, you accrue by an enrolling alteration, which in this case is the NTRK fusion.  Dr. Rafeh Naqash: Excellent. Thank you for that summary. It's interesting that just yesterday in my phase I clinic, I had an individual who was supposed to go on a certain study, and liquid biopsy came back and showed an NTRK fusion for a very odd presentation of a prostate cancer, which, again, got me thinking about the paper that you published trying to read about NTRK and then this happened and I got thinking about a bunch of other questions. But, for starters, though, from a receptor standpoint and I know you published on this in different journals, could you briefly tell, for the sake of the audience, describe the pathway and the tyrosine kinase signaling and associated resistance pathways that are concurrently acting in a different direction, perhaps, and also discuss briefly from neural development? I know the pathway, the NTRK gene or TRK gene as such is involved in different neuronal signaling aspects. Could you briefly touch on that? Dr. Alexander Drilon: Sure. And thankfully there are a lot of parallels with other things that perhaps some of the listeners are more familiar with. We'll start with the fact that it is a receptor tyrosine kinase, NTRK. It's a gene that encodes a receptor tyrosine kinase just like other receptor tyrosine kinases that may be fused such as ALK, RET, and ROS1. But remember also that other RTKs are EGFR, FGFR, which are also well known. The important thing to remember for NTRK is that you have three different genes, NTRK 1, 2, and 3 that encode three different proteins which are called TRK A, B, and C. And as you intimated, in the non-oncogenic state, these are very important for the development and the maintenance of the nervous system. And in the fused state, of course, similar to other fusions that we spoke about, the chimeric oncoprotein will drive downstream signaling and tumor growth and metastases. And in general, these cancers can be very reliant on downstream signaling in the MAP Kinase pathway but may also on occasion activate other downstream pathways like the PI3 Kinase pathway. Dr. Rafeh Naqash: And I know some of that could potentially play into resistance mechanisms for some of these first or second-generation NTRK inhibitors. From a fusion partner standpoint, the data that I came across that you're very well aware of is different fusion partners, and maybe some have a slightly better prognosis than some other fusions. But, in your practice and in your experience, does it matter what the other fusion partner is if the kinase domain is intact, meaning the signaling for the NTRK gene is intact? Have you seen any differences there from the other fusion partner standpoint? Dr. Alexander Drilon: From a patient-matching perspective, as long as you think the fusion is real, and by that I mean that you look at the report and you're sure the kinase domain is there and you're sure it's in frame, meaning connected well to the five prime partner so that the DNA strand is read through, the five prime partner does not play a major role in my deciding to give a TRK inhibitor or not. I would give anyone with a functional NTRK 1, 2, or 3 fusion a TRK inhibitor. Now, the data on whether or not select fusions do better than others is, I would say, still a little immature and perhaps conditioned by a few things. There are some of the cancers in the first bucket that we talked about, like the secretory carcinomas that harbor a recurrent event such as ETV6 NTRK3. And those cancers, in my experience in clinic, patients with those tumors can be on a TRK inhibitor for a very long time. And it's unclear if that's because of the exact fusion event or if it's because of the cancer type that might be more, say, genomically naïve compared to a gastrointestinal tumor, like a colorectal cancer with an NTRK fusion. So I hesitate to say that there are very strong and convincing data that if you have a particular five prime partner, you'll absolutely do better or worse. So, in the interim, I think the most important piece is just making sure that the event is real and actionable, and if it is, then you can give a TRK inhibitor. Dr. Rafeh Naqash: Thank you so much. I totally agree. And I think, for the sake of our listeners, as we see more and more sequencing being done on patients with cancer in the advanced stage setting especially, it's important to keep in mind when you have something that you can act on that has an actionable target that is FDA approved, then it's important to give the patient that option, especially in rare fusion events such as NTRK or TRK.   Now, you've touched upon this in your paper, but before we go into the details of the paper, specifically, I wanted you to briefly talk about the testing mechanisms which are important for some of these fusions and play into, for example, ROS1 ALK fusions also. Could you tell us what are the most appropriate ways to test for these fusions in patients harboring cancers, both from a tissue standpoint and from a blood-based assay standpoint? Dr. Alexander Drilon: This is a great question because if you don't have a test that's optimally poised to pick up an NTRK fusion, then you can't act on it. And a patient who would have benefited very durably from a TRK inhibitor won't get access to it. So there are different ways of testing for NTRK fusions, and I like to think of the central dogma here where you have DNA becomes RNA becomes protein because that really helps anchor the different types of assays that you might use. We commonly use next-generation sequencing of DNA, but even if you have a very good next-generation sequencing assay, that does have its limitations because there are some fusions that are structurally just difficult to pick up even with a great DNA-based NGS assay.  And for that reason, we and others have found that in tumors that have an equivocal NTRK fusion, or perhaps where you didn't find something but you really suspect that you missed something, particularly in cases where, historically, like congenital fibrosarcoma where you know there's a very good likelihood of finding NTRK fusion, we then reach for an RNA-based assay because at the RNA level, you've removed things like the intra-DNA based capture challenging. And so I think that from a nucleic acid standpoint, leveraging a test that looks both at DNA and RNA, maximizes the likelihood of finding this fusion. And just remember that there are different NGS assays in terms of the approach to design and some might be more Amplicon-based and that's less optimal, but the hybrid-capture-based ones tend to be better. The DNA and RNA tests can be done on tumors, and in blood, you could do a liquid biopsy. It's very hard to fish out RNA in blood given the current technology so we're still limited to circulating tumor DNA which shares the liabilities of doing DNA testing on a tumor sample. But if you find it and it looks real, then it's certainly actionable even if you detect an NTRK fusion with a liquid biopsy.  Now going back to the central dogma there, the third piece which we haven't touched on is protein. And there have been many papers published now on the utility of immunohistochemistry, and this helps you confirm that the TRK A, B, and C proteins are actually expressed. And what tends to happen is in many fusions, the chimeric oncoproteins strongly express as TRK A, B, and C that helps provide a complementary test or assay that confirms that you're dealing with something that is actionable.  So that is a very contemporary approach and a very thorough approach to looking for these NTRK fusions where you do DNA and RNA if possible. And if you still have questions, ask your pathologist to see if they can do Pan-TRK IHC. But depending on the resource environment that you're in, there are older tests like FISH which we use for ALK that can also find these fusions. RT-PCR which only finds particular events, these can detect NTRK fusions but really don't have the breadth and comprehensiveness as the other assays that we discussed like NGS.  Dr. Rafeh Naqash: Thank you so much, Alex, for that amazing summary of all the methods that potentially could help detect this rare but important event. From a therapeutic standpoint, now, taking a deeper dive into your very interesting JCO Precision Oncology paper that looked at larotrectinib data from a pooled analysis of two trials, a phase II and a phase I. Could you tell us a little background about these two trials, the patient population and what kind of data were you trying to evaluate? And then we can discuss some of the interesting results that you showcase in the paper. Dr. Alexander Drilon: It really helps as a background to realize that the initial approach to this was really on a basket trial where the programs for larotrectinib, which is a selective TRK A, B, and C inhibitor, and the other drug entrectinib, which inhibits ROS1 in addition to TRK, really accrued pediatric and adult cancers with NTRK fusions. And this paper pulls out the lung cancer subset and we'll discuss that in detail. But before getting into that, it's important to know that in the tumor agnostic data set of all patients with an NTRK fusion of any type, larotrectinib achieved a response rate of approximately 80%, entrectinib of approaching 60%, and disease control was durable with a median PFS for larotrectinib of approximately 28 months, and with entrectinib numerically, the number was lower at 11 months.   So with that background, this paper in JCO PO, in the interest of featuring the activity for lung cancers with NTRK fusions, pulled out 20 patients with NTRK fusion-positive lung cancers. And the punchline is that the activity was pretty comparable to that seen with a bigger data set. So the objective response rate was 73% and many patients had a partial response, 67% of the cases, 7% had a complete response, and really only a minority had primary progressive disease, 1 patient out of the 15 evaluable patients. These responses and clinical benefit overall were durable and the median duration of response was almost 34 months, with a median progression-free survival of almost 35 and a half months and an overall survival median of 40.7 months.  And just to talk about how that stacks up compared to other targeted therapies, this certainly is in the ballpark of some of the best ALK inhibitors that we have for ALK fusion-positive lung cancer. It's also comparable to osimertinib for EGFR mutant lung cancer. So we can confidently view TRK inhibition in lung cancers with NTRK fusions as a highly-active therapy.  Dr. Rafeh Naqash: Absolutely. I think you touched upon this earlier where in your cohort at least 50% of patients had central nervous system involvement, and it looks like larotrectinib does have CNS activity and benefit. Could you speak to the differences between potential entrectinib and larotrectinib from a CNS efficacy standpoint? And the second part of that question was going to be when you identify this fusion in patients, for example, with lung cancer, now, since TRK does have a role in neuronal development, do you think there is a role for closer CNS monitoring in these patients if they have not had brain metastasis identified because of the fact that they have an NTRK fusion? Is there some predilection for CNS involvement from a metastasis standpoint? It's just something that I've been thinking of over the last couple of days after I saw my patient who does have CNS involvement but with prostate cancer, which I have not seen in the phase I setting in all the prostate patients that I've come across. So what are your thoughts on that?  Dr. Alexander Drilon: These are great questions. In lung cancers with NTRK fusions, there is a proclivity for metastasis to the CNS. And thankfully, both of these TKIs, larotrectinib and entrectinib, do have coverage of the CNS. Now, from a design perspective, the initial thought was perhaps entrechtinib was more CNS-penetrant. But if you look at the overall response rates in patients with brain metastases and the intracranial response rates where you have patients with target lesions in the brain that you're able to measure; if you look across the aisle, entrectinib and larotrectinib have comparable results, with the objective response rate being in the order of 50% to 60% and the intracranial response rate being also in the order of about 50% to 60%. So at the end of the day, it appears as if, despite the previous hypothesis that maybe one drug would work better in the CNS than the other, we're seeing equally good effects with both drugs.  For the second question you asked, it's also a very interesting question because, like you mentioned, the TRK receptors play a role in nervous system development. But we have not observed a much higher frequency of CNS metastases in NTRK fusion-positive lung cancers or cancers in general that I know of, compared to cancers that are wild type for an oncogene or have other oncogenes. So what's more important really to think about when you sort of chew on the fact that these TRK inhibitors are involved in nervous system development are the potential side effects that you may see in patients that you treat with these TRK inhibitors. Dr. Rafeh Naqash: Absolutely. Now, from the therapy standpoint that you discuss here, duration of responses, objective responses that you saw in your analysis were very impressive for these patients with lung cancer. In your clinical practice if you see a lung cancer patient with this fusion and you treat them with larotrectinib or entrectinib, and they have, let's say, de novo CNS metastases that are asymptomatic, do you generally try the targeted therapy first and hold off, perhaps, brain directed therapy in that setting? Similar to what one would do with osimertinib perhaps or alectinib?  Dr. Alexander Drilon: Absolutely. It's the same paradigm because we know that we are seeing in a larger population of patients, just generally good activity, both extracranially and intracranially. The goal is to try to spare patients the extra side effects of doing radiation by only giving the TKI. And in practice, even outside of the trial, in patients that I've treated with CNS metastases, the activity has been very good. Dr. Rafeh Naqash: Thank you so much. Now, all TKI therapies have, unfortunately, resistance mechanisms that come up eventually, in my experience at least. What is your experience as far as understanding resistance mechanisms on TRK-based therapies and potential second options after that, whether it's second-generation TRK inhibitors or subsequent targeted therapies in this space? Dr. Alexander Drilon: Thankfully, this has been looked at extensively and I like to categorize resistance into two major groups. So there's a type of resistance which we call on-target resistance and another type which we call off-target resistance. In simple terms, cancers that acquire on-target resistance are still dependent on the NTRK or TRK pathway. And often what happens is, like with other oncogene-targeted therapy pairs, you see the acquisition of a resistance mutation in the kinase domain of NTRK 1, 2, 3 that either changes the dynamics of the kinase or sort of kicks the drug off of the binding site due to steric hindrance.  And for those patients, companies have designed next-generation TRK inhibitors that abrogate resistance, meaning they were designed so that they would work despite the presence of these resistance mutations. And a few of them include repotrectinib, talatrectinib, and selitrectinib that are thought to have activity, but there are many other newer ones that are currently being explored. I will say that there's proof of concept that has been published as well showing that patients who progress on a first-generation TRK inhibitor like larotrectinib or entrectinib who develop acquired resistance that's on-target can respond very well to a next-generation NTRK inhibitor. And while these aren't approved just yet, these are of course available in clinical trials. Now, the second major group is more problematic. This is off-target resistance. And when I describe this to patients, what I usually say is that the cancer sort of ‘phones a friend' and activates a second gene perhaps that isn't NTRK. And examples of that include KRAS or MET or BRAF, very well-known oncogenes in other contexts, but it leads to a reliance outside of the NTRK or TRK pathway per se, which still effectively reactivates the MAP kinase pathway. What to do in that situation? Well, there are select cases and there have been case reports published of patients who get a combination. Say if it's acquired MET amplification, you give a MET inhibitor with a TRK inhibitor and that combination can work. But in many other cases where you don't have access to a combination on a clinical trial or on compassionate use, then you really default to the standard of care for that cancer type. So if it's lung cancer and they've never had chemotherapy before, then it would be platinum-based chemotherapy, say with pemetrexed and a third drug, perhaps if they have lung adenocarcinoma.  Dr. Rafeh Naqash: Thank you so much. This is definitely an exciting field and exciting time to be in this space of drug development, and especially when we have so many interesting tumor-agnostic approvals that have come along in the last few years and more to come. And you've led a lot of this development with several other leaders in this field. So it was very nice discussing this with you, and hopefully, our listeners find it equally interesting and educationally relevant to what we see day in and day out as we perform more and more sequencing for patients with cancer and try to identify some of these rare or not so rare events that are targetable and can definitely change the course of a patient's therapy and outcomes. So thank you once again, Alex, for the discussion on this paper.  But before we end, we'd like to spend a couple of minutes trying to know about the investigator. So could you tell us a little bit about your career trajectory, how you started your fellowship perhaps, how you ended up in drug development, and how you've successfully contributed so much in this field to date? Dr. Alexander Drilon: Sure. So I'm originally from the Philippines, was born there, finished med school, and really wanted to come to the United States to sort of broaden my education and my residency program in internal medicine, then called St. Luke's Roosevelt under Columbia, had a program that sent people to rotate through Memorial Sloan Kettering Cancer where I currently work. So that was my first exposure with oncology. I fell in love with it and eventually became a fellow, fortunately, at Memorial Sloan Kettering. And I mentioned earlier that during that time I had subspecialized in lung cancer and there was a lot of excitement around targeted therapy for oncogene-driven lung cancer. And that was my point of entry. I saw these drugs work very well and I said that if I were in a position to develop newer agents, perhaps for other oncogenes where there wasn't anything developed just yet, that would be really cool. And that was my entry into the phase I world where things later on expanded really the tumor agnostic interrogation using the same principles that were familiar to me in the lung cancer world. And I think I've been very fortunate with the environment and the ability, especially with good in-house sequencing, to match many patients to these trials. And it's been wonderful to see several of these drugs approved. Larotrectinib was the sort of seminal tumor-agnostic approval of a targeted therapy for the first time by any regulatory body. And like you said, the hope is that we see several more of these. Dr. Rafeh Naqash: Awesome. That sounds like a very interesting, phenomenal journey that you've had, and a lot of it is also probably related to the kind of people that you met, mentors, and other people who helped you along the way. And then, of course, you've done a lot for other fellows and trainees in this space of drug development. So thank you again, Alex, for joining us, and thank you for choosing JCO Precision Oncology as a destination for your work. I look forward to interacting with you further subsequently and hopefully seeing more development in this space of novel therapies for fusions and other interesting targets in the lung cancer space.  So thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts.  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  Bio: Alexander E. Drilon, MD, is a medical oncologist specializing in the treatment of lung cancer. He is chief of early drug development service at Memorial Sloan Kettering Cancer Center. He has clinical expertise in lung cancer and early-phase clinical trials.   COIs Alexander Drilon Honoraria: Medscape, OncLive, PeerVoice, Physicians' Education Resource, Targeted Oncology, MORE Health, Research to Practice, Foundation Medicine, PeerView Consulting or Advisory Role: Ignyta, Loxo, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech/Roche, Helsinn Therapeutics, BeiGene, Hengrui Therapeutics, Exelixis, Bayer, Tyra Biosciences, Verastem, Takeda/Millennium, BerGenBio, MORE Health, Lilly, AbbVie, 14ner Oncology/Elevation Oncology, Remedica, Archer, Monopteros Therapeutics, Novartis, EMD Serono/Merck, Melendi, Repare Therapeutics Research Funding: Foundation Medicine Patents, Royalties, Other Intellectual Property: Wolters Kluwer (Royalties for Pocket Oncology) Other Relationship: Merck, GlaxoSmithKline, Teva, Taiho Pharmaceutical, Pfizer, PharmaMar, Puma Biotechnology

Claritzel Miyares Hernández, singer and composer born in Holguín Cuba and resident in Spain. He was inclined towards music, due to his family tradition, his brother is Carlos Miyares, a saxophonist who won a Grammy award in 2010 with the Afrocuban Messengers of maestro Chucho Valdés. He studied at the Esteban Salas Conservatory in Santiago de Cuba and Amadeo Roldán in Havana where he graduated in Choral Direction. She was a showgirl at the Tropicana de Cuba cabaret with the show "Un paraíso bajo las estrellas" by Santiago Alfonso in Havana and on his tour on the island of Tenerife-Canary Islands. Contestant of the Telecinco Television Program Operación Triunfo. Contestant in the 1st edition in Spain of the program "La Voz" where she is selected in the Melendi team. In his solo career he collaborates with the Dominican singer Ángela Carrasco and offers his first solo concert at the Teatro Leal in Tenerife called "Ciclo de Boleros" reveals his roots and musical influences. After several Singles and collaborations with Artists of international stature. In 2019 he begins a new stage preparing his musical project where he returns to his Latin roots with Salsa Tropical themes and more modern sounds. His first single from this project "Te equivocaste" with Ceferino Caban, a Puerto Rican producer who has won several Grammy awards, comes out at the end of 2021

On this week's episode we have Crosby Melendi, who is a digital nomad, content creator, freelancer, coach, and location-independent traveler. Crosby shares her personal experiences becoming a digital nomad and provides advice for how to get started working remotely and solo traveling as a woman. Crosby has been working remotely and traveling full-time for more than 3 years, working online as a freelance social media strategist, content creator, and digital nomad coach. She began freelancing as a senior in college with zero remote work experience, and since then, she's balanced her remote career with a 2-month car camping adventure, a year backpacking Latin America and Europe, and for the last few months, road tripping the U.S. in a travel trailer – all while documenting the journey on social media.Crosby's Instagram: @crosbygracetravelsCrosby's Website: crosbygracetravels.comCrosby's YouTube Channel: @CrosbyGraceTravelsBrianna's Instagram: @mombossinaustinPodcast Instagram: @badassbasicbitch

India Martínez visita Cuerpos especiales para presentar Nuestro mundo, su noveno álbum de estudio. De este trabajo nos explica el calvario que pasó rodando el videoclip de la canción que le da nombre, o lo perfeccionista que es Melendi a la hora de hacer un tema juntos.

Buenos días desde La Habana, soy Yoani Sánchez y en el "cafecito informativo" de este viernes 14 de octubre de 2022 comentaré estos temas: - Decenas de estudiantes de Medicina abandonan la carrera para emigrar - Con un aumento del 20,53% en un año, el cerdo es el alimento que más sube de precio - García Lorca en Cuba, diario de una resurrección - Melendi y Aymee Nuviola: Pan Para Yolanda Gracias por compartir este "cafecito informativo" y te espero para el programa del lunes. Puedes conocer más detalles de estas noticias en el diario https://www.14ymedio.com Los enlaces de hoy: Con un aumento del 20,53% en un año, el cerdo es el alimento que más sube de precio en Cuba https://informa.link/economia/aumento-cerdo-alimento-precio-Cuba_0_3404659505.html Decenas de estudiantes de Medicina cubanos abandonan la carrera para emigrar https://informa.link/sociedad/Decenas-estudiantes-Medicina-abandonan-emigrar_0_3404659504.html Las protestas se extienden a la Ciénaga de Zapata, vitrina de la Revolución cubana https://informa.link/cuba/Cuba-manifestaciones-Cienaga_de_Zapata-castrismo-apagon-regimen_0_3404059568.html En Diversionismo ideológico: Oda urgente a los noventa, por Alexis Romay https://informa.link/opinion/Oda-urgente-noventa_0_3404659501.html El sector de la construcción domina en la creación de 'mipymes' en Cuba https://informa.link/economia/construccion-domina-creacion-mipymes-Cuba_0_3404059564.html Aumentan los incidentes violentos con migrantes cubanos en México https://informa.link/internacional/Aumentan-incidentes-violentos-migrantes-cubanos-Mexico_0_3404059569.html García Lorca en Cuba, diario de una resurrección https://informa.link/cuba/Garcia-Lorca-Cuba-diario-resurreccion_0_3402859681.html

In the absence of many forensic tools yet to be invented, 18th-century investigators had their work cut out for them. This was especially true in murder cases where the victim's body was never found. These are called bodiless murders or no-body cases. In the past, no-body cases made it nearly impossible to convict anyone of […]

Today on the podcast Mitko (@mitkoka) is joined by Crosby Melendi (@CrosbyGraceTravels), a freelancer, entrepreneur, and content creator.Mitko first came across Crosby's work on Instagram where she has almost 100,000 followers and routinely shares tips about working remotely and what it's like to live as a full-time digital nomad. Crosby has been freelancing since college and shared her top advice on how to land that all-important first client, how to navigate the Instagram algorithm to grow your social media following, and much much more.You can find all the resources and links mentioned in this interview in this episode's show notes.